Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 8

Country deep-dive

What semaglutide actually costs in the UK

NHS patients may pay £9.90 per item in England, while NICE lists Wegovy packs at £73.25 to £175.80 before a confidential NHS discount.

8 Nov 2026 · PeptideMethods Editorial Team · 6 min read
Country deep-dive

Semaglutide UK status: what changed

Semaglutide remains prescription-only in the UK, with 2026 changes to Wegovy doses, tablets, liver-disease use and product safety information.

8 Nov 2026 · PeptideMethods Editorial Team · 6 min read
Country deep-dive

Can you import Semax into the UK?

Great Britain exempts household medicine imports from one licence rule, but that does not approve Semax, validate a seller or guarantee parcel release.

8 Nov 2026 · PeptideMethods Editorial Team · 8 min read
Country deep-dive

What Semax actually costs in the UK

Zero official UK Semax prices were found. MHRA and EMA checks identified no authorised pack to price, and vendor listings are excluded.

8 Nov 2026 · PeptideMethods Editorial Team · 6 min read
Trial readouts

Antidiabetic Drug Evidence in 2026

A 2026 pharmacology review maps modern diabetes drugs, while primary outcome trials show why class summaries cannot substitute for medicine-specific results.

7 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Mental Health After Two Obesity Treatments

A six-month cohort compared psychological outcomes after bariatric surgery and incretin therapy, including tirzepatide and semaglutide.

7 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

GLP-1 Cardiovascular Effects Over Time

A 10-trial network meta-analysis supported a class-level MACE reduction, but time-varying regimen estimates were imprecise and assumption-dependent.

7 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Food-Derived Peptides in Obese Rodents

NDP-35 and NDP-45 changed satiety hormones and body weight in rodent models, but no human trial has established efficacy or safety.

7 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Semaglutide for Secondary CV Prevention

SELECT found a 1.5-point absolute difference in major cardiovascular events, while a 2026 NICE appraisal addresses the separate NHS access question.

7 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Semaglutide and Ventricular Extrasystoles

A two-database safety analysis found disproportionate reporting of ventricular extrasystoles with semaglutide, but it cannot prove causation.

7 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Tirzepatide and Lipoedema Symptoms

A 49-woman clinic cohort found symptom improvement did not track with weight loss, but no control group means the drug effect remains uncertain.

7 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Obesity Drug Endpoints in Breast Cancer

A 2026 review argues weight and BMI alone cannot describe treatment effects during endocrine therapy for HR-positive early breast cancer.

6 Nov 2026 · PeptideMethods Editorial Team · 4 min read